Collegium Pharmaceutical, Inc.
COLLNASDAQHealthcare● Active
$33.48
+$0.10(+0.29%)
Market Cap$1.1B
P/E Ratio—
52W High$50.787
52W Low$29.08
Collegium Pharmaceutical, Inc. (COLL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · COLL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.78B | $0.63B | $0.57B | $0.46B | $0.28B |
| Cost of Revenue | $0.32B | $0.25B | $0.24B | $0.25B | $0.13B |
| Gross Profit | $0.46B | $0.38B | $0.33B | $0.21B | $0.15B |
| Gross Margin %(computed) | 59.35% | 59.76% | 57.55% | 45.15% | 54.40% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.01B |
| G&A Expenses | $0.00B | $0.17B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.28B | $0.21B | $0.16B | $0.18B | $0.13B |
| Operating Income | $0.19B | $0.17B | $0.17B | $0.03B | $0.02B |
| Operating Margin %(computed) | 23.97% | 26.91% | 29.46% | 7.18% | 6.37% |
| Interest Income | $0.01B | $0.01B | $0.02B | $0.00B | $0.00B |
| Interest Expense | $0.08B | $0.07B | $0.08B | $0.06B | $0.02B |
| Income Before Tax | $0.09B | $0.10B | $0.08B | ($0.03B) | ($0.00B) |
| Income Tax Expense | $0.03B | $0.03B | $0.03B | ($0.00B) | ($0.07B) |
| Net Income | $0.06B | $0.07B | $0.05B | ($0.03B) | $0.07B |
| Net Margin %(computed) | 8.05% | 10.96% | 8.50% | -5.39% | 25.83% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.98 | $2.14 | $1.60 | $-0.74 | $2.05 |
| Wtd Avg Shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B |
| EBITDA | $0.40B | $0.34B | $0.31B | $0.17B | $0.09B |
| EBITDA Margin %(computed) | 51.37% | 54.11% | 54.40% | 37.36% | 31.26% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Collegium Pharmaceutical, Inc. data
About Collegium Pharmaceutical, Inc. (COLL) Income Statement
Collegium Pharmaceutical, Inc. (COLL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, COLL reported revenue of $0.78B, gross profit of $0.46B (gross margin 59.35%), and net income of $0.06B — a net profit margin of 8.05%.
Frequently asked questions
COLL · 4 questionsCollegium Pharmaceutical, Inc. (COLL) reported revenue of $0.78B for 2025, up 23.6% year-over-year.
COLL revenueCOLL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08